Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Moderna reminds the markets of biotech’s dual purpose
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Abbott’s speedy Covid-19 test comes under fire
Abbott’s coronavirus RNA test can ID NOW – but maybe not definitively.
Big Pharma remains bullish in the face of Covid-19
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
Quidel wins the Covid-19 antigen test race
Antigen tests are faster and cheaper than viral RNA assays, but are notably less accurate.
Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
Roche takes on Abbott in Covid-19 antibody testing
Robust specificity data mark Roche’s serological test out as a major competitor.
Lonza to do the heavy lifting for Moderna’s Covid-19 vaccine
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
The crucial trials Medtronic has had to pause
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Astrazeneca moves to upstage Moderna in Covid-19 vaccines
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Moderna reminds the markets of biotech’s dual purpose
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Abbott’s speedy Covid-19 test comes under fire
Abbott’s coronavirus RNA test can ID NOW – but maybe not definitively.
Big Pharma remains bullish in the face of Covid-19
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
